At LivaNova, we understand the importance of bringing both clinical and economic value to our customers. We are a strong, market-leading medical technology and solutions company, offering a diverse product portfolio and global reach.

LivaNova is listed on the NASDAQ stock exchange under the ticker symbol "LIVN."

Understanding the LivaNova Business

LivaNova has a workforce of approximately 4,000 employees worldwide. We are headquartered in London (UK) and maintain a presence in more than 100 countries. LivaNova operates as two businesses:

• Cardiovascular We are a global leader in cardiovascular solutions with an established leadership position in heart-lung machines and recognition as the world’s #1 cardiopulmonary bypass company. Plus, we offer the only truly sutureless aortic valve replacement, Perceval^®. Our advanced technologies have made significant contributions to cardiac surgery and provided positive outcomes for many patients who have needed cardiac and cardiopulmonary support.
• Neuromodulation As pioneers of the VNS (Vagus Nerve Stimulation) Therapy^® System, we continue to advance medical device solutions for people affected by drug-resistant epilepsy and treatment-resistant depression. This System is also being studied to validate its ability to deliver Autonomic Regulation Therapy for heart failure. Additionally, we treat obstructive sleep apnea (OSA) with an implantable device that stimulates multiple tongue muscles via the hypoglossal nerve, opening the airway while a patient is sleeping.

LIVN Strategic Portfolio Initiatives

Our product portfolio has multiple strategic portfolio initiatives (SPIs), which are mid- to long-term growth drivers for the company. These SPIs include:

• VNS Therapy for Treatment-Resistant Depression (TRD): Depression is the leading cause of disability worldwide, and VNS Therapy may provide better outcomes and symptom improvement for patients with TRD.
• Transcatheter Mitral Valve Replacement (TMVR): Nearly 1 in 10 people age 75 or older has moderate to severe Mitral Regurgitation. ^1,2 LivaNova is conducting a clinical trial for the Caisson TMVR, which uses a tube (catheter) through an incision in the groin instead of open-heart surgery to replace the mitral valve.
• VITARIA^® for Heart Failure: The leading cause of morbidity and mortality is heart failure. Using its VNS Therapy System, LivaNova's novel delivery of Autonomic Regulation Therapy may improve regulation of cardiovascular function.

LivaNova is improving the quality of life through innovation for every patient, every day.

1. Lloyd-Jones D, Adams RJ, Brown ^TM, et al; American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics—2010 update: a report from the American Heart Association. Circulation. 2010;121(7):e46-e215.
2. Nkomo VT, Gardin JM, Skelton TN, Gottdiener JS, Scott CG, Enriquez-Sarano M. Burden of valvular heart diseases: a population-based study. Lancet. 2006;368(9540):1005-1011.